Angiodynamics (ANGO) EBIT (2010 - 2026)

Angiodynamics has reported EBIT for 17 years, with the latest figure at -$13.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT fell 29.85% year-over-year to -$13.0 million; the trailing twelve-month figure through Feb 2026 stood at -$35.5 million (up 26.94% YoY), and the FY2025 full-year result was -$40.0 million, up 79.24% from the prior year.
• EBIT for Q1 2026 stood at -$13.0 million, down from -$6.1 million in the prior quarter.
• The five-year high for EBIT was $35.0 million in Q3 2023, with the low at -$199.9 million in Q1 2024.
• Historically, EBIT has averaged -$19.1 million across 5 years, with a median of -$10.7 million in 2025.
• Annual changes were most pronounced in 2023 — EBIT surged 363.36% — and 2024, when it slumped 2138.98%.
• Angiodynamics' EBIT stood at -$8.1 million in 2022, then tumbled by 61.68% to -$13.1 million in 2023, then grew by 15.44% to -$11.1 million in 2024, then surged by 44.79% to -$6.1 million in 2025, then slumped by 111.44% to -$13.0 million in 2026.
• The last three EBIT figures came in at -$13.0 million (Q1 2026), -$6.1 million (Q4 2025), and -$10.7 million (Q3 2025), per Business Quant data.